Precision medicine is an innovative approach to disease prevention and treatment that takes into account individual differences in people’s genes, environments, and lifestyles. The aim is to accelerate biomedical discoveries and give clinicians the tools and knowledge to individualize care.
The conference will offer a high level discussion of the scientific, economic and regulatory landscape of precision medicine and what the future implications are for providers, patients, payers, policymakers and the pharmaceutical industry.
The Center for Health Policy is a joint program of the University of Virginia School of Medicine, Department of Public Health Sciences and the Frank Batten School of Leadership and Public Policy.
Monday, November 2
Mark McClellan, Keynote Address and Public Forum
Precision Medicine: Framing the Issues
Tuesday, November 3
8:45 – 9 a.m.
Welcome and Opening Remarks, Eric Patashnik, Director, Center for Health Policy, University of Virginia
9 – 10:30 a.m.
Panel 1: Precision Medicine – The Promise of More Effective Treatment
Moderator: Carolyn Engelhard, Associate Director, Center for Health Policy, University of Virginia
Panelists: Steven Schondelmeyer, UMN; Mike Pacanowski, FDA; Carolyn Clancy, Veterans Health Administration
Panel 2: Realizing the Promise – Economic Challenges & Policy Barriers to Precision Medicine
Moderator: Robert Meyer, Director, Va. Center for Translational and Regulatory Sciences, University of Virginia
Panelists: Bob Hugin, Celgene; Joe Antos, American Enterprise Institute; Bill Hazel, Va. Secretary of Health and Human Resources
Panel 3: Making Precision Medicine a Reality – Next Step for Stakeholders
Moderator: Mimi Riley, U.Va. School of Law
Panelists: Jeff Chodakewitz, Vertex Pharmaceuticals; Chip Kahn, Federation of American Hospitals; Greg Daniel, Brookings Institution
Closing Remarks, Eric Patashnik
A senior fellow and director of the Health Care Innovation and Value Initiative at the Brookings Institution, McClellan is a doctor and economist by training.
With a distinguished career in research and public service, McClellan is a former administrator of the Centers for Medicare & Medicaid Services (CMS) and former commissioner of the U.S. Food and Drug Administration (FDA). He previously served as a member of the President’s Council of Economic Advisers, senior director for health care policy at the White House and was an associate professor of economics and medicine at Stanford University.
McClellan holds an MD from the Harvard University–Massachusetts Institute of Technology (MIT) Division of Health Sciences and Technology, a PhD in economics from MIT, an MPA from Harvard University and a BA from the University of Texas at Austin. He completed his residency training in internal medicine at Boston’s Brigham and Women’s Hospital, is board-certified in Internal Medicine and has been a practicing internist during his career.